Business · 11/04/2018Updated: 10/17/2026 · 1 min read
FDA Renews Bone, Reproductive and Urologic Drugs Advisory Committee for 2 Years
The FDA has renewed the Bone, Reproductive and Urologic Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on March 23, 2020.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →